Complete Filing Data
Inhibikase Therapeutics, Inc. reported Stockholders Equity of $172.90 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Inhibikase Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income Loss | -$48.3M | -$27.5M | -$19.0M | -$18.1M | -$14.8M | -$2.8M |
| Selling General And Administrative Expense | $23.6M | $11.4M | $6.7M | $6.2M | $6.5M | $2.6M |
| Research And Development Expense | $29.8M | $17.2M | $13.6M | $12.0M | $11.4M | $893.8K |
| Operating Income Loss | -$52.0M | -$28.6M | -$20.1M | -$18.1M | -$14.8M | -$2.8M |
| Revenue From Contract With Customer Excluding Assessed Tax | $0.00 | $260.5K | $123.4K | $3.1M | $698.5K | |
| Other Comprehensive Income Loss Tax | $59.1K | -$38.1K | -$103.8K | $104.7K | ||
| Interest Income Expense Net | $3.7M | $1.1M | $1.1M | $74.5K | -$19.9K | |
| Interest Expense | $19.9K | $29.4K | ||||
| Other Comprehensive Income Loss Net Of Tax | -$48.2M | -$27.6M | -$19.1M | -$17.9M | -$14.8M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$11.9M | -$9.9M | -$13.7M | -$5.8M | -$5.0M | -$4.6M | -$4.6M | -$5.8M | -$4.5M | -$4.5M | -$4.6M | -$4.6M | -$4.5M | -$2.6M | -$2.6M | -$670.6K | -$421.9K | -$547.4K |
| Selling General And Administrative Expense | $5.6M | $5.9M | $5.2M | $1.6M | $2.0M | $2.0M | $1.6M | $1.8M | $1.9M | $1.5M | $1.7M | $1.7M | $1.6M | $1.6M | $1.6M | $580.8K | $370.3K | $527.7K |
| Research And Development Expense | $7.6M | $5.3M | $10.5M | $4.2M | $3.1M | $2.8M | $3.2M | $4.5M | $2.9M | $3.0M | $3.0M | $3.0M | $3.2M | $2.4M | $2.4M | $120.6K | $263.2K | $283.1K |
| Operating Income Loss | -$12.8M | -$10.8M | -$14.6M | -$5.8M | -$5.1M | -$4.8M | -$4.8M | -$6.2M | -$4.7M | -$4.5M | -$4.6M | -$4.6M | -$4.5M | -$2.6M | -$2.6M | -$663.7K | -$413.9K | -$540.0K |
| Revenue From Contract With Customer Excluding Assessed Tax | $0.00 | $0.00 | $0.00 | $79.6K | $116.4K | $64.5K | $7.3K | $6.6K | $46.0K | $328.5K | $1.4M | $1.4M | $37.7K | $219.6K | $270.8K | |||
| Other Comprehensive Income Loss Tax | -$1.2K | -$2.0K | $36.3K | $2.8K | $776.00 | -$2.7K | $1.6K | -$167.5K | $61.1K | $26.8K | ||||||||
| Interest Income Expense Net | $838.1K | $916.8K | $919.3K | $49.4K | $90.9K | $132.7K | $173.7K | $424.4K | $237.2K | $18.5K | $0.00 | -$5.00 | ||||||
| Interest Expense | $0.00 | $5.00 | $157.00 | $7.8K | $11.8K | $6.9K | $7.9K | $7.4K | ||||||||||
| Other Comprehensive Income Loss Net Of Tax | -$11.9M | -$9.9M | -$13.6M | -$5.8M | -$5.0M | -$4.7M | -$4.4M | -$4.5M | -$4.6M | -$4.5M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $172.9M | $94.9M | $11.0M | $21.0M | $38.4M | $9.8M | -$4.5M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $139.2M | $56.5M | $9.2M | $7.2M | $40.8M | $14.0M | $18.5K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $82.7M | $47.3M | $2.0M | -$33.6M | $26.8M | $13.9M | |
| Retained Earnings Accumulated Deficit | -$142.7M | -$94.4M | -$66.9M | -$47.9M | -$29.8M | $15.0M | |
| Prepaid Expense And Other Assets Current | $343.4K | $826.5K | $739.2K | $163.5K | $1.5M | $54.8K | |
| Liabilities And Stockholders Equity | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M | $14.8M | |
| Liabilities | $8.3M | $3.7M | $3.5M | $3.9M | $4.1M | $5.0M | |
| Common Stock Value | $131.7K | $69.4K | $6.2K | $4.2K | $25.2K | $10.1K | |
| Assets | $181.2M | $98.6M | $14.5M | $24.9M | $42.5M | $14.8M | |
| Additional Paid In Capital Common Stock | $315.4M | $189.3M | $77.9M | $68.8M | $68.2M | $24.8M | |
| Accrued Liabilities Current | $4.1M | $2.7M | $2.3M | $2.4M | $2.7M | $632.9K | |
| Accounts Payable Current | $1.2M | $943.0K | $646.8K | $1.2M | $1.1M | $1.7M | |
| Marketable Securities Unrealized Gain Loss | $59.1K | -$38.1K | -$103.8K | $104.7K | $0.00 | ||
| Liabilities Current | $8.3M | $3.7M | $3.4M | $3.7M | $4.1M | $4.7M | |
| Assets Current | $180.1M | $98.5M | $14.2M | $24.4M | $42.5M | ||
| Non Cash Consulting Fees | $0.00 | $31.5K | $67.0K | $60.4K | $148.8K | ||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $21.8K | -$37.2K | $877.00 | $104.7K | $0.00 | ||
| Property Plant And Equipment Net | $0.00 | $47.1K | $73.4K | $236.5K | $0.00 | ||
| Repayments Of Notes Payable | $0.00 | $248.9K | $42.5K | $0.00 | |||
| Operating Lease Right Of Use Asset | $0.00 | $101.4K | $222.2K | $328.6K | $0.00 | ||
| Marketable Securities Current | $39.5M | $41.1M | $4.1M | $15.9M | $0.00 | ||
| Long Term Debt And Capital Lease Obligations Current | $0.00 | $110.5K | $150.1K | $145.8K | $0.00 | ||
| Maturities Of Investments Marketable Securitie | $41.6M | $23.5M | $41.1M | $5.0M | $0.00 | ||
| Accounts And Other Receivables Net Current | $39.9K | $110.1K | $0.00 | ||||
| Non Cash PPP Loan Forgiveness | $0.00 | $27.6K | $0.00 | ||||
| Notes Payable Current | $42.5K | ||||||
| Capital Lease Obligations Noncurrent | $205.5K | $0.00 | |||||
| Long Term Notes Payable | $0.00 | $276.5K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $72.9M | $80.1M | $85.7M | -$530.6K | $5.1M | $6.8M | $15.0M | $19.5M | $25.3M | $25.1M | $29.5M | $34.0M | $43.2M | $47.1M | $8.0M | -$5.1M | -$4.8M | -$4.7M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $38.3M | $77.7M | $73.4M | $913.4K | $3.1M | $2.4M | $14.9M | $1.9M | $4.0M | $5.8M | $32.2M | $36.6M | $44.8M | $46.8M | $9.6M | $16.2K | $7.8K | $13.1K | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $17.0M | -$6.8M | -$3.2M | -$4.1M | -$4.3M | -$5.3K | |||||||||||||||
| Retained Earnings Accumulated Deficit | -$129.9M | -$118.0M | -$108.1M | -$82.3M | -$76.5M | -$71.6M | -$62.7M | -$58.1M | -$52.3M | -$43.6M | -$39.1M | -$34.5M | -$24.8M | -$20.3M | -$17.7M | ||||||
| Prepaid Expense And Other Assets Current | $618.8K | $682.6K | $932.0K | $280.9K | $356.5K | $851.1K | $371.5K | $543.9K | $922.8K | $505.9K | $811.5K | $1.2M | $541.4K | $834.0K | $1.2M | ||||||
| Liabilities And Stockholders Equity | $79.6M | $88.9M | $94.3M | $4.4M | $8.8M | $11.1M | $17.9M | $22.3M | $28.2M | $28.6M | $34.0M | $38.4M | $45.9M | $49.2M | $11.9M | ||||||
| Liabilities | $6.7M | $8.8M | $8.6M | $4.9M | $3.7M | $4.3M | $2.9M | $2.9M | $2.8M | $3.4M | $4.5M | $4.4M | $2.7M | $2.2M | $3.8M | ||||||
| Common Stock Value | $74.8K | $74.5K | $74.3K | $7.5K | $7.2K | $6.5K | $5.4K | $5.3K | $31.1K | $25.2K | $25.2K | $25.2K | $25.2K | $25.1K | $10.1K | ||||||
| Assets | $79.6M | $88.9M | $94.3M | $4.4M | $8.8M | $11.1M | $17.9M | $22.3M | $28.2M | $28.6M | $34.0M | $38.4M | $45.9M | $49.2M | $11.9M | ||||||
| Additional Paid In Capital Common Stock | $202.8M | $198.0M | $193.8M | $81.7M | $81.6M | $78.3M | $77.7M | $77.6M | $77.5M | $68.7M | $68.6M | $68.4M | $67.9M | $67.3M | $25.7M | ||||||
| Accrued Liabilities Current | $3.7M | $3.1M | $3.5M | $2.2M | $2.0M | $2.5M | $1.9M | $1.8M | $1.6M | $2.3M | $3.6M | $3.6M | $1.9M | $872.8K | $627.4K | ||||||
| Accounts Payable Current | $620.5K | $2.7M | $1.7M | $2.5M | $1.3M | $1.3M | $734.6K | $754.1K | $959.1K | $781.2K | $860.4K | $806.2K | $553.8K | $897.2K | $715.0K | ||||||
| Marketable Securities Unrealized Gain Loss | -$1.2K | -$2.0K | $36.3K | $2.8K | $776.00 | -$2.7K | $1.6K | -$167.5K | $61.1K | $26.8K | $0.00 | $0.00 | $0.00 | ||||||||
| Liabilities Current | $6.7M | $8.8M | $8.6M | $4.9M | $3.7M | $4.2M | $2.7M | $2.7M | $2.7M | $3.2M | $2.7M | $1.9M | $3.6M | ||||||||
| Assets Current | $78.5M | $88.8M | $94.2M | $4.2M | $8.6M | $10.8M | $17.6M | $22.0M | $27.6M | $28.0M | $33.9M | $11.9M | $14.8M | ||||||||
| Non Cash Consulting Fees | $0.00 | $67.0K | $60.4K | $37.5K | |||||||||||||||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$4.2K | -$2.9K | -$967.00 | $1.8K | -$1.0K | -$1.8K | -$143.00 | -$1.7K | $165.8K | $26.8K | |||||||||||
| Property Plant And Equipment Net | $0.00 | $23.7K | $47.8K | $53.7K | $60.2K | $66.8K | $79.9K | $86.5K | $231.5K | $241.6K | $43.1K | ||||||||||
| Repayments Of Notes Payable | $0.00 | $248.9K | $409.7K | ||||||||||||||||||
| Operating Lease Right Of Use Asset | $0.00 | $34.9K | $68.7K | $133.1K | $163.8K | $193.5K | $250.1K | $277.1K | $303.3K | $353.3K | |||||||||||
| Marketable Securities Current | $39.1M | $9.9M | $19.7M | $2.3M | $4.9M | $7.4M | $2.0M | $19.0M | $21.8M | $20.8M | |||||||||||
| Long Term Debt And Capital Lease Obligations Current | $0.00 | $37.9K | $74.8K | $145.2K | $152.2K | $151.2K | $149.0K | $148.0K | $146.9K | $142.0K | |||||||||||
| Maturities Of Investments Marketable Securitie | $21.5M | $5.1M | $15.8M | $0.00 | |||||||||||||||||
| Accounts And Other Receivables Net Current | $0.00 | $0.00 | $0.00 | $79.6K | $64.5K | $13.8K | $6.6K | $48.0K | |||||||||||||
| Non Cash PPP Loan Forgiveness | $0.00 | $27.6K | |||||||||||||||||||
| Notes Payable Current | $0.00 | $0.00 | $0.00 | $248.9K | $248.9K | $994.8K | |||||||||||||||
| Capital Lease Obligations Noncurrent | $58.3K | $90.1K | $121.0K | $150.0K | $178.1K | $232.0K | |||||||||||||||
| Long Term Notes Payable | $0.00 | $248.9K | $248.9K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Proceeds From Issuance Of Common Stock | $107.6M | $103.5M | $8.5M | $0.00 | $0.00 | $4.9K |
| Share Based Compensation | $15.3M | $8.1M | $500.1K | $458.1K | $1.5M | $573.7K |
| Net Cash Provided By Used In Operating Activities | -$27.8M | -$19.1M | -$18.1M | -$17.4M | -$14.3M | -$1.1M |
| Net Cash Provided By Used In Financing Activities | $108.5M | $103.5M | $8.4M | -$204.8K | $41.1M | $15.1M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$532.7K | $616.5K | $55.4K | -$1.3M | $1.4M | $37.9K |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | $1.4M | $420.1K | -$138.5K | -$317.3K | $2.1M | -$1.1M |
| Increase Decrease In Accounts Payable | $146.8K | $271.8K | -$504.4K | $61.4K | -$630.9K | -$247.1K |
| Increase Decrease In Prepaid Research And Development | $1.9M | -$138.5K | -$897.8K | $1.0M | -$667.4K | |
| Increase Decrease In Accounts Receivable | $0.00 | -$39.9K | $39.9K | $110.1K | $0.00 | |
| Net Cash Provided By Used In Investing Activities | $2.1M | -$37.0M | $11.7M | -$16.0M | $0.00 | |
| Proceeds From Stock Options Exercised | $845.5K | $0.00 | $0.00 | $44.1K | $78.5K | $0.00 |
| Payments To Acquire Marketable Securities | $39.1M | $60.5M | $29.4M | $20.7M | $0.00 | |
| Payments To Acquire Property Plant And Equipment | $13.4K | $0.00 | $14.2K | $243.3K | $0.00 | |
| Increase Decrease In Deferred Revenue | $0.00 | -$2.3M | $897.1K | |||
| Increase Decrease In Operating Lease Right Of Use Assets | $101.4K | $120.8K | $106.4K | $38.1K | ||
| Increase Decrease In Operating Lease Liabilities | $110.5K | $129.7K | $111.1K | $9.9K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q4 2022 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|---|
| Proceeds From Issuance Of Common Stock | $0.00 | $397.6K | $1.0M | $1.0M | $0.00 | $4.9K | |
| Share Based Compensation | $2.0M | $53.4K | $123.3K | $123.2K | $591.1K | $139.8K | |
| Net Cash Provided By Used In Operating Activities | -$4.1M | -$3.9M | -$6.0M | -$3.9M | -$3.9M | -$255.4K | |
| Net Cash Provided By Used In Financing Activities | $0.00 | $367.0K | $8.6M | -$204.8K | -$409.7K | $250.1K | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $211.9K | $14.7K | $759.3K | -$337.7K | -$200.6K | -$3.0K | |
| Increase Decrease In Other Accounts Payable And Accrued Liabilities | $833.2K | $247.6K | -$840.2K | $858.2K | -$5.5K | $133.7K | |
| Increase Decrease In Accounts Payable | $680.8K | $479.3K | -$192.1K | -$283.6K | -$1.0M | -$255.9K | |
| Increase Decrease In Prepaid Research And Development | -$28.8K | -$12.4K | -$194.5K | $458.3K | -$61.7K | ||
| Increase Decrease In Accounts Receivable | $0.00 | $24.6K | -$62.2K | $332.8K | |||
| Net Cash Provided By Used In Investing Activities | $21.1M | -$3.3M | -$5.8M | $0.00 | |||
| Proceeds From Stock Options Exercised | $0.00 | $44.1K | $0.00 | ||||
| Payments To Acquire Marketable Securities | $0.00 | $8.4M | $21.6M | $0.00 | |||
| Payments To Acquire Property Plant And Equipment | $13.4K | $0.00 | |||||
| Increase Decrease In Deferred Revenue | $0.00 | -$1.1M | $43.0K | ||||
| Increase Decrease In Operating Lease Right Of Use Assets | $32.7K | $28.8K | $25.4K | $0.00 | |||
| Increase Decrease In Operating Lease Liabilities | $35.7K | $30.7K | $26.3K | $0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.49 | -$1.16 | -$3.16 | -$4.28 | -$0.81 | -$0.35 |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Issued | 131.7M | 69.4M | 6.2M | 4.2M | 25.2M | 10.1M |
| Weighted Average Number Of Shares Outstanding Basic | 98.3M | 23.7M | 6.0M | 4.2M | 18.2M | |
| Weighted Average Number Of Diluted Shares Outstanding | 98.3M | 23.7M | 6.0M | 4.2M | 18.2M | |
| Earnings Per Share Basic | $-0.49 | $-1.16 | $-3.16 | $-4.28 | $-0.81 | |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 131.7M | 69.4M | 6.2M | 4.2M | 25.2M | 10.1M |
| Common Stock Shares Authorized | 500.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M |
| Weighted Average Number Of Share Outstanding Basic And Diluted | 18.2M | 8.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.13 | -$0.11 | -$0.15 | -$0.65 | -$0.66 | -$0.73 | -$0.86 | -$1.11 | -$0.98 | -$1.06 | -$1.10 | -$0.18 | -$0.18 | -$0.22 | -$0.26 | -$0.08 | -$0.05 | -$0.07 |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $5.50 | ||
| Common Stock Shares Issued | 74.8M | 74.5M | 74.3M | 7.5M | 7.2M | 6.5M | 5.4M | 5.3M | 31.1M | 25.2M | 25.2M | 25.2M | 25.2M | 25.1M | 10.1M | |||
| Weighted Average Number Of Shares Outstanding Basic | 90.1M | 90.0M | 89.5M | 8.9M | 7.5M | 6.3M | 5.3M | 5.2M | 4.6M | 4.2M | 4.2M | 25.2M | 25.1M | 12.2M | ||||
| Weighted Average Number Of Diluted Shares Outstanding | 90.1M | 90.0M | 89.5M | 8.9M | 7.5M | 6.3M | 5.3M | 5.2M | 4.6M | 4.2M | 4.2M | 25.2M | 25.1M | 12.2M | ||||
| Earnings Per Share Basic | $-0.13 | $-0.11 | $-0.15 | $-0.65 | $-0.66 | $-0.73 | $-0.86 | $-1.11 | $-0.98 | $-1.06 | $-1.10 | $-0.18 | $-0.18 | $-0.22 | ||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Outstanding | 74.8M | 74.5M | 74.3M | 7.5M | 7.2M | 6.5M | 5.4M | 5.3M | 31.1M | 25.2M | 25.2M | 25.2M | 25.2M | 25.1M | 10.1M | |||
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | 100.0M | |||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 25.2M | 25.1M | 12.2M | 10.1M | 8.2M | 8.2M | 8.2M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $15.3M | $8.1M | $500.1K | $458.1K | $1.5M | $573.7K |
| Costs And Expenses | $52.0M | $28.6M | $20.4M | $18.3M | $17.9M | $3.5M |
| Prepaid Expense Current | $1.0M | $81.3K | $219.8K | $1.1M | $107.0K | $774.4K |
| Depreciation | $60.5K | $26.3K | $177.4K | $6.7K | $0.00 | |
| Fair Value Adjustment Of Warrants | $0.00 | $688.8K | $1.4M | |||
| Stock Issued During Period Value Other | $110.1M | $103.3M | $8.6M | $111.1K | ||
| Stock Issued During Period Value New Issues | $67.0K | $60.4K | $4.9K | |||
| Interest Paid Net | $0.00 | $973.00 | $1.1K | $6.2K | ||
| Issuance Costs | $7.4M | $11.5M | $1.5M | |||
| Stock Issued During Period Value Stock Options Exercised | $845.5K | $44.1K | ||||
| Change In Fair Value Contingent Consideration | $1.4M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $4.5M | $4.2M | $2.0M | $148.0K | $30.7K | $53.4K | $129.8K | $124.8K | $123.3K | $101.8K | $132.8K | $123.2K | $352.4K | $322.5K | $591.1K | $139.8K | $139.8K | $139.8K | ||
| Costs And Expenses | $12.8M | $10.8M | $14.6M | $5.8M | $5.1M | $4.8M | $4.8M | $6.3M | $4.8M | $4.5M | $4.6M | $4.7M | $4.8M | $4.0M | $4.0M | $701.4K | $633.5K | $810.8K | ||
| Prepaid Expense Current | $210.6K | $138.9K | $52.5K | $112.2K | $306.3K | $207.4K | $347.6K | $425.2K | $923.1K | $932.4K | $919.1K | $565.3K | $264.4K | $958.8K | $712.7K | |||||
| Depreciation | $23.7K | $24.2K | $12.7K | $6.6K | $6.6K | $6.6K | $6.6K | $159.2K | $5.0K | $1.7K | $0.00 | $0.00 | ||||||||
| Fair Value Adjustment Of Warrants | $0.00 | $181.8K | $239.4K | $237.8K | $236.4K | $89.5K | $191.0K | |||||||||||||
| Stock Issued During Period Value Other | $150.00 | $2.5M | $24.00 | $3.2M | $397.6K | $17.4K | $95.00 | $8.5M | ||||||||||||
| Stock Issued During Period Value New Issues | $385.9K | $385.9K | $385.9K | $67.0K | $1.9M | $1.5M | $60.4K | $4.9K | ||||||||||||
| Interest Paid Net | $0.00 | $973.00 | $11.8K | $1.8K | ||||||||||||||||
| Issuance Costs | $0.00 | $407.3K | $1.4M | $0.00 | ||||||||||||||||
| Stock Issued During Period Value Stock Options Exercised | $250.9K | $31.6K | $44.1K | $44.1K | -$43.3K | |||||||||||||||
| Change In Fair Value Contingent Consideration | $492.8K | $358.4K | $1.2M | $0.00 | $0.00 | $0.00 |
Most recent annual filing with the SEC: March 26, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.